Glucagon‐like peptide‐1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of… Click to show full abstract
Glucagon‐like peptide‐1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of the budget impact associated with GLP1 insurance coverage requires estimates of GLP1 prices that account for manufacturer discounts. The authors applied a peer‐reviewed method to estimate the net prices of GLP1s after manufacturer discounts.
Keywords:
antiobesity medications;
new antiobesity;
prices new;
net prices
Journal Title: Obesity
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Obesity
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!